Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double‐blind, randomized, placebo‐controlled phase I/II trial
- 1 November 1999
- journal article
- clinical trial
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 14 (11), 1093-1099
- https://doi.org/10.1046/j.1440-1746.1999.02008.x
Abstract
Background: In Japan, glycyrrhizin therapy is widely used for chronic hepatitis C and reportedly reduces the progression of liver disease to hepatocellular carcinoma. The aims of this study were to evaluate the effect of glycyrrhizin on serum alanine aminotransferase (ALT), hepatitis C virus (HCV)-RNA and its safety in European patients. Methods: Fifty-seven patients with chronic hepatitis C, non-responders or unlikely to respond (genotype 1/cirrhosis) to interferon therapy, were randomized to one of the four dose groups: 240, 160 or 80 mg glycyrrhizin or placebo (0 mg glycyrrhizin). Medication was administered intravenously thrice weekly for 4 weeks; follow up also lasted for 4 weeks. Results: Within 2 days of start of therapy, serum ALT had dropped 15% below baseline in the three dosage groups (P < 0.02). The mean ALT decrease at the end of active treatment was 26%, significantly higher than the placebo group (6%). A clear dose–response effect was not observed (29, 26, 23% ALT decrease for 240, 160 and 80 mg, respectively). Normalization of ALT at the end of treatment occurred in 10% (four of 41). The effect on ALT disappeared after cessation of therapy. During treatment, viral clearance was not observed: the mean decrease in plasma HCV-RNA after active treatment was 4.1 × 106 genome equivalents/mL (95% confidence interval, 0–8.2 × 106; P > 0.1). No major side-effects were noted. None of the patients withdrew from the study because of intolerance. Conclusions: Glycyrrhizin up to 240 mg, thrice weekly, lowers serum ALT during treatment, but has no effect on HCV-RNA levels. The drug appears to be safe and is well tolerated. In view of the reported long-term effect of glycyrrhizin, further controlled investigation of the Japanese mode of administration (six times weekly) for induction appears of interest. © 1999 Blackwell Science Asia Pty LtdKeywords
This publication has 13 references indexed in Scilit:
- Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis CHepatology, 1998
- Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis CThe Lancet, 1998
- Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfaHepatology, 1997
- Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfaHepatology, 1997
- Effect of glycyrrhizin on viral replication and quasispecies in patients with type C chronic hepatitisInternational Hepatology Communications, 1997
- Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typingJournal of General Virology, 1995
- Therapeutic Approach to the Chronic Active Liver Disease: Summary of a Satellite SymposiumPublished by Springer Nature ,1994
- Glycyrrhizic acid in liquorice—Evaluation of health hazardFood and Chemical Toxicology, 1993
- MINERALOCORTICOID ACTIVITY OF LIQUORICE: 11-BETA-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY COMES OF AGEThe Lancet, 1987
- Enzyme leakage due to change of membrane permeability of primary cultured rat hepatocytes treated with various hepatotoxins and its prevention by glycyrrhizinCell Biology and Toxicology, 1985